Docoh
Loading...

MDT Medtronic

Medtronic plc, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Company profile

Ticker
MDT
Exchange
CEO
Geoffrey Martha
Employees
Location
Fiscal year end
Former names
Medtronic Holdings Ltd, Medtronic Ltd
SEC CIK
Subsidiaries
2074417 Alberta ULC • A&E Products de Honduras S.A. • A&E Products do Brasil Ltda. • A&E Products Group, Inc. • Advanced Absorbent Products Holdings Limited • Advanced Medical Technologies GmbH • AI Biomed Corp • Aircraft Medical Ltd. • Airox, Inc. • Arterial Vascular Engineering Canada, Company ...

MDT stock data

(
)

Calendar

2 Sep 21
17 Oct 21
29 Apr 22
Quarter (USD)
Jul 21 Apr 21 Jan 21 Oct 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Apr 21 Apr 20 Apr 19 Apr 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Medtronic earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 3B 3B 3B 3B 3B 3B
Cash burn (monthly) 196.33M 291.25M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 510.07M 756.66M n/a n/a n/a n/a
Cash remaining 2.49B 2.25B n/a n/a n/a n/a
Runway (months of cash) 12.7 7.7 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
8 Oct 21 Parkhill Karen L Ordinary Shares Gift Acquire G Yes No 0 12,000 0 49,859
8 Oct 21 Parkhill Karen L Ordinary Shares Gift Dispose G No No 0 12,000 0 35,974
6 Oct 21 Parkhill Karen L Ordinary Shares Gift Acquire G Yes No 0 37,859 0 37,859
6 Oct 21 Parkhill Karen L Ordinary Shares Gift Dispose G No No 0 37,859 0 47,974
30 Sep 21 Lerman Bradley E Ordinary Shares Sell Dispose S No Yes 126.58 49,147 6.22M 48,763
30 Sep 21 Lerman Bradley E Ordinary Shares Option exercise Acquire M No Yes 78 49,147 3.83M 97,910
30 Sep 21 Lerman Bradley E Stock Option Ordinary Shares Option exercise Dispose M No Yes 78 49,147 3.83M 0
31 Aug 21 Lerman Bradley E Ordinary Shares Sell Dispose S No Yes 134.17 50,775 6.81M 48,763
31 Aug 21 Lerman Bradley E Ordinary Shares Option exercise Acquire M No Yes 74.84 50,775 3.8M 99,538
31 Aug 21 Lerman Bradley E Stock Option Ordinary Shares Option exercise Dispose M No Yes 74.84 50,775 3.8M 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

78.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1856 1831 +1.4%
Opened positions 141 116 +21.6%
Closed positions 116 111 +4.5%
Increased positions 795 806 -1.4%
Reduced positions 679 679
13F shares
Current Prev Q Change
Total value 146.31B 125.33B +16.7%
Total shares 1.06B 1.06B -0.4%
Total puts 4.81M 4.94M -2.6%
Total calls 6.57M 6.41M +2.5%
Total put/call ratio 0.7 0.8 -5.0%
Largest owners
Shares Value Change
Vanguard 111.78M $13.88B +0.6%
BLK Blackrock 104.62M $12.99B -2.0%
STT State Street 55.85M $6.97B +2.1%
Massachusetts Financial Services 46.11M $5.72B -3.6%
Wellington Management 33.45M $4.15B -2.3%
JPM JPMorgan Chase & Co. 25.94M $3.22B +14.7%
Lazard Asset Management 24.6M $3.05B +1.7%
BAC Bank Of America 23.59M $2.93B -0.8%
TROW T. Rowe Price 22.69M $2.82B +3.3%
Geode Capital Management 21.81M $2.7B +1.8%
Largest transactions
Shares Bought/sold Change
Amundi 7.42M +7.42M NEW
Amundi Pioneer Asset Management 0 -6.49M EXIT
BK Bank Of New York Mellon 15.05M -4.2M -21.8%
Capital Research Global Investors 18.54M +3.34M +22.0%
JPM JPMorgan Chase & Co. 25.94M +3.33M +14.7%
Boston Partners 2.48M -3.18M -56.2%
Citadel Advisors 152.25K -2.8M -94.8%
Sanders Capital 10.33M +2.15M +26.2%
BLK Blackrock 104.62M -2.14M -2.0%
IVZ Invesco 9.42M +2.04M +27.7%

Financial report summary

?
Risks
  • We operate in a highly competitive industry and we may be unable to compete effectively.
  • The ongoing global COVID-19 pandemic has had, and may continue to have, an adverse effect on certain aspects of our business, results of operations, financial condition and cash flows. The nature and extent of future impacts are highly uncertain and unpredictable.
  • Reduction or interruption in supply or other manufacturing difficulties may adversely affect our manufacturing operations and related product sales.
  • Our research and development efforts rely upon investments and investment collaborations, and we cannot guarantee that any previous or future investments or investment collaborations will be successful.
  • The continuing development of many of our products depends upon us maintaining strong relationships with healthcare professionals.
  • Our substantial leverage and debt service obligations could adversely affect our business.
  • Failure to integrate acquired businesses into our operations successfully, as well as liabilities or claims relating to such acquired businesses, could adversely affect our business.
  • Climate change, or legal, regulatory or market measures to address climate change may materially adversely affect our financial condition and business operations.
  • We are subject to extensive and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations.
  • Our failure to comply with laws and regulations relating to reimbursement of healthcare goods and services may subject us to penalties and adversely impact our reputation, business, results of operations, financial condition and cash flows.
  • We are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to our rights or the rights of others may result in our payment of significant monetary damages and/or royalty payments, negatively impacting our ability to sell current or future products.
  • Quality problems and product liability claims could lead to recalls or safety alerts, reputational harm, adverse verdicts or costly settlements, and could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Healthcare policy changes may have a material adverse effect on us.
  • Our insurance program may not be adequate to cover future losses.
  • The failure to comply with anti-corruption laws could materially adversely affect our business and result in civil and/or criminal sanctions.
  • Laws and regulations governing international business operations could adversely impact our business.
  • We are subject to environmental laws and regulations and the risk of environmental liabilities, violations and litigation.
  • We rely on the proper function, security and availability of our information technology systems and data, as well as those of third parties throughout our global supply chain, to operate our business, and a breach, cyber-attack or other disruption to these systems or data could materially and adversely affect our business, results of operations, financial condition, cash flows, reputation or competitive position.
  • Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial condition and cash flows.
  • The Medtronic, Inc. tax court proceeding outcome could have a material adverse impact on our financial condition.
  • Future potential changes to the U.S. tax laws could result in us being treated as a U.S. corporation for U.S. federal tax purposes, and the IRS may not agree with the conclusion that we should be treated as a foreign corporation for U.S federal income tax purposes.
  • Legislative or other governmental action relating to the denial of U.S. federal or state governmental contracts to U.S. companies that redomicile abroad could adversely affect our business.
  • We are incorporated in Ireland, and Irish law differs from the laws in effect in the U.S. and may afford less protection to holders of our securities.
  • As an Irish public limited company, certain capital structure decisions require shareholder approval, which may limit Medtronic’s flexibility to manage its capital structure.
  • A transfer of our shares, other than ones effected by means of the transfer of book-entry interests in the Depository Trust Company, may be subject to Irish stamp duty.
  • In certain limited circumstances, dividends we pay may be subject to Irish dividend withholding tax and dividends received by Irish residents and certain other shareholders may be subject to Irish income tax.
  • Our shares received by means of a gift or inheritance could be subject to Irish capital acquisitions tax.
  • If we experience decreasing prices for our goods and services and we are unable to reduce our expenses, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.
  • We are subject to a variety of risks associated with global operations that could adversely affect our profitability and operating results.
  • Consolidation in the healthcare industry could have an adverse effect on our revenues and results of operations.
  • Healthcare industry cost-containment measures could result in reduced sales of our medical devices and medical device components.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: Abre, adaptive, affiliate, Arctic, Artic, awaiting, body, cerebral, circulatory, confidence, confirm, CPV, cryoablation, Cyber, deliverability, Delta, Denervation, downturn, encryption, esophageal, expressly, frequency, Front, FSB, FX, GL, grew, Hugo, HVAD, hypertension, incident, Intersect, intrasaccular, Intrepid, lesser, light, List, MCS, mitral, mortality, newly, NICU, noncash, notification, notwithstanding, NPWMD, OFAC, ordinarily, Panama, provincial, RAS, RC, repaid, repayment, respectfully, Russia, Russian, SDN, SHA, SonarMed, Sonicision, source, Spyral, stop, Symplicity, tag, tricuspid, uneven, unwanted, variant, visibility, WACC, wafer
Removed: absolute, accrue, accurately, adequately, adversely, affirmed, affordable, alleged, ample, anticipation, appellate, appendectomy, arise, assessed, assist, assumed, auction, bariatric, bear, belief, breached, bring, broad, bundled, CABG, calculate, calendar, cancel, Cardinal, certification, challenged, challenging, characterized, closed, closely, collectability, Colorectal, competitor, complex, continuity, County, CRT, dealing, declaration, deductible, degree, delay, delayed, deleveraging, denying, derecognize, deteriorate, discretionary, dismissed, disrupt, disrupted, divested, divestiture, doubtful, ECMO, encounter, enjoin, entity, establish, establishment, Estimating, Ethicon, examined, existed, expiration, expired, Extracorporeal, facing, fall, FASB, favor, featured, fiduciary, forma, Foundation, granting, greater, grow, Gynecological, half, Hennepin, hybrid, hysterectomy, iii, indemnified, infringement, injunctive, Insufficiency, intent, interrupted, invested, investor, iv, Kenneth, knowledge, launch, lease, leaving, legislative, loop, LVAD, macroeconomic, maintaining, maintenance, marketplace, matured, Medicare, member, Merenstein, methodology, Minnesota, Moderately, modest, monetary, motion, multitude, noting, Nutritional, obsolescence, obstruction, occupancy, occur, offer, Ohio, oncology, outlined, Paclitaxel, parameter, permanently, petition, portion, precisely, preliminary, prevail, prevent, prioritize, programming, properly, pursued, putative, quarantine, raw, realize, record, reevaluate, reinvested, reliability, relief, remained, reorganization, repatriate, repatriation, resource, response, resumption, resurgence, retrospective, reversed, reversing, robot, scalable, scheduled, seeking, sending, set, simplify, Southern, speed, spending, staffing, Steiner, supportable, Supreme, sustained, technical, Titan, transplant, transportation, travel, Treasury, twelve, ultimately, uncertainty, undrawn, urgent, vast, ventricular, visualization, workforce, worldwide